The Pfizer-BioNtech Covid-19 vaccine, sold under the brand ‘Comirnaty’, may require a third dose to work more effectively against the coronavirus (Covid-19). The third Kovid-19 shot is also expected to provide better protection against the beta variant. News agencies gave this information citing a statement on Friday morning.
Pfizer-Biotech announced on Thursday that they will seek regulatory approval for its Covid-19 vaccine. The company will try to get approval in view of interim trial data, which revealed that the third dose could raise antibody levels five to ten times as much as the first two doses. The company is also trying to get approval for the third dose.
Pfizer up to 64% effective on delta variants
Recently there were reports that the vaccine is less effective against delta variants of the SARS-CoV-2 virus. According to a report, Pfizer is up to 64 percent effective in preventing the impact of delta variants on fully vaccinated people, according to data collected in the last one month. Earlier, the vaccine was up to 94 per cent effective in other variants of corona.
This is what the Israeli government said
Israel’s government also said this week that the impact of the Pfizer-Biotech vaccine is reportedly diminishing after 6 months. According to a report, Data from Israel’s Health Ministry shows that Pfizer’s Covid-19 vaccine protected 64 percent of the country’s people between June 6 and July early July. Whereas, earlier the figure was at 94 percent.